Medigene Presents Final Phase I Data of TCR-T Cell Therapy MDG1011 in Patients With High-Risk Blood Cancers

Medigene AG reported final Phase I dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy for high-risk myeloid and lymphoid neoplasms.